CN106890352A - A kind of bioactive functions dressing for treating diabetes - Google Patents
A kind of bioactive functions dressing for treating diabetes Download PDFInfo
- Publication number
- CN106890352A CN106890352A CN201710149517.0A CN201710149517A CN106890352A CN 106890352 A CN106890352 A CN 106890352A CN 201710149517 A CN201710149517 A CN 201710149517A CN 106890352 A CN106890352 A CN 106890352A
- Authority
- CN
- China
- Prior art keywords
- layer
- dressing
- bioactive functions
- bioactive
- functions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
- A61L15/325—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/24—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
- A61L2300/208—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61L2300/254—Enzymes, proenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
The present invention discloses a kind of bioactive functions dressing for treating diabetes.The dressing is made up of bioactive functions layer, antibacterial functions layer, liquid suction function layer, organism pressure functional layer；Bioactive functions layer, antibacterial functions layer, liquid suction function layer, organism pressure functional layer are followed successively by from the bottom up.Dressing structure of the present invention is simple, and manufacturing cost is low, low cost, while easy to operate, treatment and treatment of the greatly convenient doctor with medical personnel to diabetes wound；The active component of bioactive functions layer has slow releasing function, can promote surface of a wound capillary network, the reparation of nerve by the effect of active bio composition, effective stimulus, the activation of promotion diabetes surface of a wound cell and regeneration.Dressing of the present invention has nerve and vascular lesion reparation, efficiently anti-infective and surface of a wound imbibition apocenosis, and dressing to biomechanical effect of wound etc., and with multi-functional, therapeutic effect is good, can be widely applied to diabetic foot and the nursing of clinic.
Description
Technical field
The present invention relates to functional dressings in medicine equipment, especially a kind of bioactive functions for treating diabetes
Dressing.
Background technology
With expanding economy and the change of people's lives mode and aging population, diabetic (mainly II
Patients with type Ⅰ DM) quantity increase sharply, present Epidemiological state.Report from the World Health Organization, the whole world is existing within 2013
3.82 hundred million adults suffer from diabetes, and oneself turns into the common disease and frequently-occurring disease of many countries in the whole world to diabetes, and its death rate is
The 3rd after intentions angiosis, tumour.
Compared with developed countries, China's diabetes prevalence is also than relatively low, but, China's diabetes prevalence growth rate
But it is the most fast country in the whole world, adds our large population base, therefore, diabetes illness Population is very surprising！According to
The Diabetes Epidemiological Investigation result of diabetology branch of Chinese Medical Association announcement in 2013, China has had up to 1.14 hundred million
Diabetic, up to 11.6%, China has been referred to as the first in the world diabetes big country to more than 30 years old crowd's diabetes prevalence.
The World Health Organization points out that, such as custom of or else making the life better, to the year two thousand forty, diabetic's number of China will increase to 1.5 hundred million.
And, diabetes are presented the trend that becomes younger in China.
With regard to current medical level, diabetes cannot be effected a radical cure, and such as without suitable control, can cause a series of complication.
The healthy and life of the complication of diabetes then serious harm people, the life to Chinese produces significant impact, causes
The quality of life of patient declines, and Happiness Index declines, and causes huge economy and society to bear.
Diabetes, also known as diabetic acromelic gangrene, are the Complicated with Severe of diabetic angiopathy and peripheral neuropathy
Disease, with it is acral send out cool, numb, pain, accompanying infection, ulcer, in addition gangrene be main clinical manifestation.At present, in clinic
In the amputation of generation, 50% or so because diabetes cause gangrene and produce, diabetes have been diabetics
The Tough questions for facing.Data display, about 25% diabetic can occur sufficient bursting in certain period of life
Ulcer, illness rate rises year by year.Just having one in many countries in west, every 20 patients has ulcer medical history, about 1% glycosuria
Patient can be by amputation.Health ministry Department of Disease Control data shows, diabetes be current China diabetic disable,
One of lethal major reason, seriously threatens quality of life and the age in longevity of patient.
From the point of view of diabetes pathology physiology, the main cause for producing diabetes is diabetic angiopathy and nerve
Lesion, infects the generation for also further triggering and aggravating diabetes with immune decline in addition.
Therefore, research and development are applied to the modern dressing of diabetic foot, as focus of concern.But, from
From the point of view of authorizing invention disclosed patent at present, the dressing of most or unitary function, for example, patent CN 102949709B, public
Opened it is a kind of treat external-use gel preparation of diabetes and preparation method thereof, it is specific comprising a group hEGF
(rhEGF), shitosan antibacterial material and oxygen carrying material perfluorodecalin or perfluorotributylamine, also relate to stabilizer, NMF,
Penetrating agent, surfactant and pH adjusting agent etc..The deficiency of the patent is merely, with rhEGF, not account for CO2 laser weld, separately
Outward, antibiosis use merely shitosan, and the effect to Gram-negative bacteria, Pseudomonas aeruginosa, some harmful fungoids is inadequate.Diabetes
Patient is low due to body immunity, the migrans and phagocytic activity reduction of leucocyte, makes it easier to generation infection and is difficult to control
System, and mostly gram positive bacterial infection, coagulant increases during blood is made after infection, and local oxygen consumption increases, and makes ischaemic
Aggravate and gangrene occurs.
Patent CN103083226B discloses a kind of preparation of the gel containing fibroblast growth factor modifier
Method and the application in the chronic ulcer of skin treatment that diabetes cause, the invention gel is by recombinant human fibroblast
The modifier of Porcine HGF -1 (FGF-1135) albumen, low molecular weight heparin sodium, glycerine, protein protective agent, gel-type vehicle and
Water for injection etc. is constituted.
Patent CN103041438B discloses a kind of moist anti-bacterial hydrogel dressing for treating diabetic foot ulcer, is to pass through
Silver iron compound is dissolved in sodium alginate aqueous solution, adds reducing agent to obtain Nano Silver sodium alginate soln, make Nano Silver
Sodium alginate soln enters in bacteria cellulose film, freeze-dried to obtain bacteria cellulose/Nano Silver sodium alginate composite membrane,
Composite membrane is immersed in calcium chloride water again, obtains a kind of moist anti-bacterial hydrogel dressing for treating diabetic foot ulcer,
The dressing is the compound water congealing glued membrane of bacteria cellulose aquagel and the calcium alginate hydrogel composition containing Nano Silver.
Patent CN101721681A discloses a kind of new application of human horny cell growth factor-2, is applied to diabetic foot
And the treatment of leg ulcer and leg ulcer, using the life of the specificity promotion epithelial cell proliferation of human horny cell growth factor-2
Thing activity, repairs to epithelial damage, reaches the treatment to diabetic foot and leg ulcer.
Patent CN102210853 A disclose one kind and contain epithelical cell growth factor (EGF) and transdermal small peptide fusion egg
The preparation method of the white liposome for preventing and treating diabetic foot gangrene, it is to be given birth to epidermis using organic solvent reverse evaporation
The factor (EGF) long and transdermal small peptide fusion protein inclusion get up, in addition, the relatively low EGF of selection and transdermal small peptide fusion protein
Content is formulated.
Patent CN104474535 A disclose a kind of water-soluable gel for treating diabetes, including active collagen (I) is dilute
Liquid, moisturizing agent, bactericide and auxiliary material etc. are released, the life that natural macromolecular active collagen (I type) has is assigned using water-soluable gel
Thing information, induces the Regeneration and Repair of body tissue capilary, to reach the purpose of body recovery.
Patent CN105749332A discloses a kind of preparation method of the activity gels sponge for diabetic ulcer, including
Active layer gel and protective layer gel, devise preparation, the preparation of protective layer gel of active layer gel, then by active layer gel
Frozen drying is combined and carried out with protective layer gel, gel sponge is formed, and sterilizing to prepare after packing completes.
Other disclosed patents are all some treatment diabetes dressing patents containing Chinese medicine.
From the point of view of the product being clinically applied at present, most of dressing are external products, such as include Denmark
The Kang Huier dressing series of Mentor Corp., the medical treatment of the dressing of brightness company of Xerox of Britain, the dressing of Johson ＆ Johnson, Monick, Sweden
Mei Pikang series dressing of articles for use Co., Ltd etc..
Simultaneously, it can be seen that due to the complexity of diabetes pathogenesis, at present both at home and abroad also not dedicated for controlling
The biological function dressing of diabetes is treated, only has certain wound healing to act on for clinical a small amount of dressing, not only valency
Lattice are high, and without specific aim, effect also not enough significantly, the aspect such as idicatio, function and curative effect and cost performance also much without
The need for method meets the huge market of China and sufferer.
From for current existing patent and product, generally existing is not enough as follows：
(1) it is that vascular lesion, DPN and immunity function are answered by infection is undermined not consider diabetes
Result is closed, with its complexity, and existing invention or product are single certain 1 to 2 kind of function of consideration, it is such as simply simple to introduce
Growth factor, or plus antibacterial, or plus imbibition etc., therefore, resultant effect is not good；
(2) all inventions all do not account for the situation of nerve damage, therefore corresponding function is not taken in dressing yet；
(3) some dressing employ shitosan as anti-biotic material, in fact, simple shitosan is negative to the blue bodyguard of leather
The effect of bacterium, pseudomonas aeruginosa and tolerant Pseudomonas aeruginosa, Pseudomonas aeruginosa, Candida albicans, anthrax-bacilus etc. all not enough shows
Write, it is impossible to really play anti-infectious function；
(4) current domestic high-touch feature dressing is few, it is impossible to meet the huge demand in market；
(5) price of the dressing that offshore company uses on Chinese Clinical is generally higher.
According to the deficiency of functional dressings enumerated above, the present invention develops a kind of new functional dressings.
The content of the invention
In order to overcome the shortcoming and deficiency of prior art, it is an object of the invention to provide one kind for treating diabetes
Bioactive functions dressing.The invention provides it is a kind of can comprehensive diabetes pathogenesis and the biology that designs and produces is living
The multi-functional dressing of property.
The purpose of the present invention is achieved through the following technical solutions：
Due to diabetes chronic metabolic disorder, abnormal hemorheology in patients, Adherence of Platelet and concentration is caused to increase
By force, blood coagulability increases, and causes circulation and nervous system dysfunction, in addition local compression, wound, infection, is to trigger
There is the main cause of diabetes (acromelic gangrene) complication in diabetic.
Therefore, this project in terms of vascular lesion, DPN and infection three, is come for the pathogenesis of diabetes
Design construction first, for nerve and vascular lesion, draws dedicated for the novel bioactive functional dressings of diabetic foot
Enter nerve growth factor, Ahylysantinfarctase isoreactivity composition, carry out stimulating vascular endothelial cell to discharge histiotype plasminogen etc., reach
Thrombus, anti-freezing, improvement microcirculation and nerve regneration purpose；Secondly, it has already been proven that, diabetes make patient extracellular base occur
The relative or absolute shortage of matter, cell factor and corresponding acceptor etc., slows down skin histology healing rate, and this is also glycosuria
Foot disease it is refractory more the reason for one of, therefore, improve diabetes wound at oxygen content, suppress wound at bacterial growth and increase
Growth factor content promotes wound healing for treatment diabetes important in inhibiting at wound.Here, we are by introducing
The Porcine HGFs such as EGF, BFGF, and micromolecule polypeptide come stimulate surface of a wound cell differentiation with regeneration, wound healing；
Third, because abnormal carbohydrate metabolism not only occurs in diabetic, and leukocyte function is damaged with cellular immune function, easily feels
Dye, due to the presence of vascular lesion and DPN, small wound can cause the invasion and attack and infection of microorganism, and infect
It is easy to diffusion, superficial infection not only occurs, and the infection of extensive deep layer easily occur, is the chief threat of diabetes,
Because infection is local, and takes antibiotic and not only develop immunity to drugs, and patient body is damaged, we think deeply use and are difficult
Drug resistance is produced, and has broad-spectrum antiseptic efficiency quaternary phosphines cation and season to gram-positive bacteria, negative bacterium and harmful fungoid
Ammonium cation compound, produces synergy, reaches efficient antibacterial, anti-infection effect；Fourth, due to most of diabetes
Dryness with it is moist and deposit, it may appear that infection is suppurated, it is necessary to give apocenosis debridement in time, therefore, in the design of dressing, we
Using the water-soluble high-molecular material of good biocompatibility, by optimized proportioning, efficient imbibition apocenosis composition is built；Its
Five, due to the sensitivity and fragility of diabetic cutaneous, inappropriate pressure can increase wound healing time, such as footwear
Power produces local pressure, will also result in the obturation of blood vessel, is further exacerbated by ulcer etc., therefore, our lifes according to diabetes
Thing mechanical requirements, design can both enable dressing fit the surface of a wound using the rubber elastomer shell of compression of adjustable governor pressure, play most
Big efficiency, can avoid producing wound inappropriate pressure, influence healing again；Finally, in the work of comprehensive dressing various functions
In the case of mechanism and structure-activity relationship, obtain and prepare the life for being applied to China's patient with diabetic feet with independent intellectual property right
The key technology and method of thing functional dressings, to reach the development level of lifting China medical apparatus industry, mitigate diabetes
The pain of patient, benefits the purpose of our people.
Concrete operations mode of the present invention is：
A kind of bioactive functions dressing for treating diabetes, the dressing is by bioactive functions layer, antibacterial work(
Ergosphere, liquid suction function layer, the part of organism pressure functional layer four composition.Bioactive functions layer is orlop, from the bottom up the
Two layers is antibacterial functions layer, and third layer is liquid suction function layer, and the 4th layer (the superiors) are biological pressure functional layer.
Wherein, bioactive functions layer is by active scaffold, nerve growth factor, EGF (epithelical cell growth factor), bFGF
The material such as (basic fibroblast growth factor), Ahylysantinfarctase is constituted.The active scaffold by NTx albumen, by Static Spinning
Silk is produced, and is combined self-assembly activity peptide again above.Then, nerve growth factor, EGF, bFGF, the load of Ahylysantinfarctase isoreactivity material
On active scaffold.Nerve growth factor, EGF, bFGF, Ahylysantinfarctase isoreactivity material are lived by liposomal, liposome control
The slow releasing function of property material.The purpose of this layer is the effect by active bio composition, stimulates, promotes diabetes surface of a wound cell
Activation and regeneration, stimulate surface of a wound capillary network, the reparation of nerve.
Described self-assembly activity peptide is L6D2With two kinds of compounds of peptide of ALPs；The active peptide is L6D2, as with parent
Aqueous aspartic acid (D) head, and hydrophobic leucine (L) afterbody small-molecular peptides, and amphipathic lipopeptid ALPS,
It is composited by molecular self-assembling.
Antibacterial functions layer is made up of chitin fiber film Yu quaternary alkylphosphonium salt, modified quaternary ammonium salt of chitosan, and season is loaded on tunica fibrosa
Phosphonium salt and modified quaternary ammonium salt of chitosan.The purpose of this layer is, by shitosan and quaternary phosphonium salt, the synergy of quaternary ammonium salt, to produce super
The harmful microbe killing actions such as additive effect, Gram-negative bacteria, gram-positive bacteria, fungi, virus to wound, keep away
Exempt from infection, inflammation, suppuration of wound etc..Additionally, chitin fiber film with holes is also for the outflow of wound liquid provides passage.
Liquid suction function layer is by methyl methacrylate and hydroxyethyl methacrylate copolymer, sodium carboxymethylcellulose, third
Triol by being composited, in the functional layer methyl methacrylate and hydroxyethyl methacrylate copolymer level be 20~
40%th, carboxymethylcellulosodium sodium content is that 40~60%, glycerol content is 10~20%.Thickness is 500~1000 microns.It is logical
Best of breed is crossed, has best absorption to the liquid that the surface of a wound is produced.
Organism pressure functional layer is made up of latex film, and film thickness carries a diameter of 20~50 above at 100~500 microns
The micropore of micron.The film is by caoutchouc latex, by deproteination matter, then by after presulfurization, pore-foaming agent treatment, passing through
Film forming, vulcanisation step are prepared.The purpose of this layer is by the high resiliency of natural emulsion, in the situation that periphery is adhesively fixed
Under, while dressing core can be made to be brought into close contact the surface of a wound, give wound one suitable pressure, promote biosphere active component more
The good embodiment played with other each layer action function effects, meanwhile, the hole on latex film can allow oxygen, vapor etc. easily
It is penetrating, further improve the therapeutic effect of dressing.
Finally, four functional layers for making organically are combined with each other, produce functional dressings of the invention, wherein, system
The bioactive functions layer of work, antibacterial functions layer, liquid suction function layer length and width it is all consistent, and be in the organism pressure work(of the superiors
Ergosphere goes out 20~30 millimeters than this three slice width, and three layers of bioactive functions layer, antibacterial functions layer, liquid suction function layer etc. is placed on life
Thing pressure functional layer centre, i.e. organism pressure functional layer edge leave 10~15 millimeters of blank, for coating medical level
Pressure-sensitive adhesion glue, by adhesive glue, the dressing is fixed on surface of a wound skin.
As preferred scheme, by the RGF of liposomal, bFGF, nerve growth factor, Ahylysantinfarctase and self-assembly activity
Peptide activity composition is produced by Ji'nan University's genetically engineered drug national project center and Guangdong,Hongkong and Macao central nerve regeneration research institute, or
Produced by Lang Tai pharmaceutical Co. Ltds of Guangdong Nanhai.
Used as preferred scheme, the thickness of active scaffold is 80~300 microns, and aperture is 20~60 microns.
Used as preferred scheme, chitin fiber film is formed by weaving by a diameter of 10~20 microns of chitin fiber,
The fiber film thickness is 200~300 microns, and aperture is 30~60 microns.
Used as preferred scheme, the quaternary phosphonium salt loaded on tunica fibrosa is using Ji'nan University's patent of invention
(CN102020675B) the vinyl tri-phenyl-phosphorus bromide for preparing.
Used as preferred scheme, latex film is the enzyme process using the production of Product processing research institute of Chinese Academy of Tropical Agricultural Sciences
Deproteinization natural emulsion is prepared from.
The present invention has the following advantages and effect relative to prior art：
(1) dressing structure of the present invention is simple, and manufacturing cost is low, low cost, while easy to operate, greatly convenient doctor
Treatment and treatment with medical personnel to diabetes wound；
(2) Pathological Physiology that the present invention falls ill according to diabetes, has considered vascular injury, nerve damage and sense
Situations such as dye, be immunized decline with the factor such as infection, carried out multi-functional compound, the functional dressings of generation have nerve and blood vessel
Lesion is repaired, efficiently anti-infective and surface of a wound imbibition apocenosis, and dressing is to biomechanical effect of wound etc., with multi-functional,
Therapeutic effect is good, can be widely applied to diabetic foot and the nursing of clinic.
(3) active component of the bioactive functions layer of present invention design has slow releasing function, can be by active bio
The effect of composition, effective stimulus, the activation of promotion diabetes surface of a wound cell and regeneration, promotes surface of a wound capillary network, nerve
Reparation；
(4) the antibacterial functions layer of present invention design passes through shitosan and quaternary phosphonium salt, the synergy of quaternary ammonium salt, with wide spectrum
The harmful microbes such as antibacterial functions, Gram-negative bacteria, gram-positive bacteria, fungi, virus to wound all have efficiently,
Lasting killing action, it is to avoid infection, inflammation, suppuration of wound etc..
(5) the liquid suction function layer of present invention design is by methyl methacrylate and hydroxyethyl methacrylate copolymer, carboxylic
Sodium carboxymethylcellulose pyce, glycerine by being composited, can efficient absorption fester form gel, play the preferably work of the cleaning surface of a wound
With.
(6) the organism pressure functional layer of present invention design is made up of deproteinization latex film, by the high-elastic of natural emulsion
Property, in the case where periphery is adhesively fixed, while dressing core can be made to be brought into close contact the surface of a wound, give wound one suitable pressure
Power, promotes the more preferable performance of bioactive functions layer active component and the embodiment of other each layer action function effects, meanwhile, latex
Hole on film can allow oxygen, vapor etc. easily penetrating, further improve the therapeutic effect of dressing.
Brief description of the drawings
Fig. 1 is the front view for treating the bioactive functions dressing of diabetes of the invention；Wherein, (1)-biology
Active function layer, (2)-antibacterial functions layer, (3)-liquid suction function layer, (4)-organism pressure functional layer.
Fig. 2 is the top view for treating the bioactive functions dressing of diabetes of the invention, i.e. (4)-biological pressure
Power functional layer and microcellular structure above.
Specific embodiment
With reference to embodiment and accompanying drawing, the present invention is described in further detail, but embodiments of the present invention are not limited
In this.
Embodiment 1
A kind of bioactive functions dressing for treating diabetes, as depicted in figs. 1 and 2, by bioactive functions
Layer, antibacterial functions layer, liquid suction function layer, the part of organism pressure functional layer four composition.Bioactive functions layer is orlop, under
The second layer up is antibacterial functions layer, and third layer is liquid suction function layer, and the 4th layer (the superiors) are biological pressure functional layer.It is raw
Thing active function layer is made up of materials such as active scaffold, nerve growth factor, EGF, bFGF, Ahylysantinfarctases.Nerve growth factor,
EGF, bFGF, Ahylysantinfarctase isoreactivity material are supported on active scaffold.The active scaffold by NTx albumen, by Static Spinning
Silk is produced, and is combined self-assembly activity peptide again above.Described self-assembly activity peptide is L6D2With two kinds of compounds of peptide of ALPs.God
Through growth factor, EGF, bFGF, Ahylysantinfarctase isoreactivity material by liposomal, the sustained release of liposome control active material is made
With.The thickness of active scaffold is 80 microns, and aperture is 20 microns.
Antibacterial functions layer is made up of chitin fiber film Yu quaternary alkylphosphonium salt, modified quaternary ammonium salt of chitosan, and chitin fiber film is
By being formed by weaving, the fiber film thickness is 200 microns to chitin fiber by a diameter of 10 microns, and aperture is 30 microns, fine
Quaternary alkylphosphonium salt and modified quaternary ammonium salt of chitosan are loaded on dimension film.
Liquid suction function layer is by methyl methacrylate and hydroxyethyl methacrylate copolymer, sodium carboxymethylcellulose, third
By being composited, methyl methacrylate and hydroxyethyl methacrylate copolymer level are 20%, carboxymethyl cellulose to triol
Plain sodium content is that 60%, glycerol content is 20%.Thickness is 500 microns.
Organism pressure functional layer is made up of latex film, and film thickness is micro- with a diameter of 20 microns above at 100 microns
Hole.
Bioactive functions layer, antibacterial functions layer, liquid suction function layer length and width it is all consistent, and be in the biological pressure of the superiors
Power functional layer goes out 20 millimeters than this three slice width, and three layers of bioactive functions layer, antibacterial functions layer, liquid suction function layer etc. is placed on life
Thing pressure functional layer centre, i.e. organism pressure functional layer edge leave 10 millimeters of blank, pressure-sensitive for coating medical level
Adhesive glue.
Embodiment 2
A kind of bioactive functions dressing for treating diabetes, as depicted in figs. 1 and 2, by bioactive functions
Layer, antibacterial functions layer, liquid suction function layer, the part of organism pressure functional layer four composition.Bioactive functions layer is orlop, under
The second layer up is antibacterial functions layer, and third layer is liquid suction function layer, and the 4th layer (the superiors) are biological pressure functional layer.It is raw
Thing active function layer is made up of materials such as active scaffold, nerve growth factor, EGF, bFGF, Ahylysantinfarctases.Nerve growth factor,
EGF, bFGF, Ahylysantinfarctase isoreactivity material are supported on active scaffold.The active scaffold by NTx albumen, by Static Spinning
Silk is produced, and is combined self-assembly activity peptide again above.Described self-assembly activity peptide is L6D2With two kinds of compounds of peptide of ALPs.God
Through growth factor, EGF, bFGF, Ahylysantinfarctase isoreactivity material by liposomal, the sustained release of liposome control active material is made
With.The thickness of active scaffold is 300 microns, and aperture is 60 microns.
Antibacterial functions layer is made up of chitin fiber film Yu quaternary alkylphosphonium salt, modified quaternary ammonium salt of chitosan, and chitin fiber film is
By being formed by weaving, the fiber film thickness is 300 microns to chitin fiber by a diameter of 20 microns, and aperture is 60 microns, fine
Quaternary alkylphosphonium salt and modified quaternary ammonium salt of chitosan are loaded on dimension film.
Liquid suction function layer is by methyl methacrylate and hydroxyethyl methacrylate copolymer, sodium carboxymethylcellulose, third
By being composited, methyl methacrylate and hydroxyethyl methacrylate copolymer level are 40%, carboxymethyl cellulose to triol
Plain sodium content is that 50%, glycerol content is 10%.Thickness is 1000 microns.
Organism pressure functional layer is made up of latex film, and film thickness is micro- with a diameter of 50 microns above at 500 microns
Hole.
Bioactive functions layer, antibacterial functions layer, liquid suction function layer length and width it is all consistent, and be in the biological pressure of the superiors
Power functional layer goes out 30 millimeters than this four slice width, and four layers of bioactive functions layer, antibacterial functions layer, liquid suction function layer etc. is placed on life
Thing pressure functional layer centre, i.e. organism pressure functional layer edge leave 15 millimeters of blank, pressure-sensitive for coating medical level
Adhesive glue.
SD rats 160 are taken, wherein 40 is normal control, another 120 intraperitoneal injection Streptozotocins make diabetes
Model.120 rats are divided into model group, experimental group at random, and positive controls make together with Normal group in rat back
Full thickness dermal wounds, Normal group and model group surface of a wound external application sterilizing vaseline, experimental group external application this dressing are positive right
According to a group other products for external application market purchase, then by 1~4 week, each group wound healing area and angiogenesis are observed
Situation.Result shows, compared with Normal group, positive controls, this dressing promotes the speed of diabetes Wound Defect healing
Substantially high and wound healing quality is also significantly improved.
Above-described embodiment is the present invention preferably implementation method, but embodiments of the present invention are not by above-described embodiment
Limitation, it is other it is any without departing from Spirit Essence of the invention and the change, modification, replacement made under principle, combine, simplification,
Equivalent substitute mode is should be, is included within protection scope of the present invention.
Claims (10)
1. a kind of bioactive functions dressing for treating diabetes, it is characterised in that：The dressing is by bioactive functions
Layer, antibacterial functions layer, liquid suction function layer, the part of organism pressure functional layer four composition；Bioactive functions layer is orlop, under
The second layer up is antibacterial functions layer, and third layer is liquid suction function layer, and the 4th layer is biological pressure functional layer.
2. the bioactive functions dressing for treating diabetes according to claim 1, it is characterised in that：
Described bioactive functions layer, antibacterial functions layer, liquid suction function layer length and width it is all consistent, and organism pressure functional layer ratio
This three slice width goes out 20~30 millimeters, and bioactive functions layer, antibacterial functions layer, liquid suction function layer are placed on organism pressure functional layer
10~15 millimeters of blank is left in centre, i.e. organism pressure functional layer edge, for coating medical level pressure-sensitive adhesion glue, leads to
Adhesive glue is crossed, the dressing is fixed on surface of a wound skin.
3. the bioactive functions dressing for treating diabetes according to claim 1 and 2, it is characterised in that：
Described bioactive functions layer is made up of active scaffold, nerve growth factor, EGF, bFGF, Ahylysantinfarctase；Nerve growth
The factor, EGF, bFGF, Ahylysantinfarctase are supported on active scaffold.
4. the bioactive functions dressing for treating diabetes according to claim 3, it is characterised in that：
Described active scaffold is produced by NTx albumen by electrostatic spinning, is combined self-assembly activity peptide again above；It is described
Active scaffold thickness be 80~300 microns, aperture be 20~60 microns.
5. the bioactive functions dressing for treating diabetes according to claim 4, it is characterised in that：Described
Self-assembly activity peptide is L6D2With two kinds of compounds of peptide of ALPs.
6. the bioactive functions dressing for treating diabetes according to claim 1 and 2, it is characterised in that：
Described antibacterial functions layer is made up of chitin fiber film Yu quaternary alkylphosphonium salt, modified quaternary ammonium salt of chitosan, is loaded on tunica fibrosa
Quaternary alkylphosphonium salt and modified quaternary ammonium salt of chitosan；The thickness of described chitin fiber film is 200~300 microns, and aperture is 30~60
Micron.
7. the bioactive functions dressing for treating diabetes according to claim 1 and 2, it is characterised in that：
Described liquid suction function layer by methyl methacrylate and hydroxyethyl methacrylate copolymer, sodium carboxymethylcellulose,
Glycerine is by being composited；Thickness is 500~1000 microns.
8. the bioactive functions dressing for treating diabetes according to claim 7, it is characterised in that：
Methyl methacrylate and hydroxyethyl methacrylate copolymer level are 20~40%, carboxylic in described liquid suction function layer
Methylcellulose sodium content is that 40~60%, glycerol content is 10~20%.
9. the bioactive functions dressing for treating diabetes according to claim 1 and 2, it is characterised in that：
Described organism pressure functional layer is made up of latex film, film thickness at 100~500 microns, above with a diameter of 20~
50 microns of micropore.
10. the bioactive functions dressing for treating diabetes according to claim 9, it is characterised in that：
Described organism pressure functional layer be by caoutchouc latex, by deproteination matter, then by presulfurization, pore-foaming agent at
After reason, it is prepared by film forming, vulcanisation step.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710149517.0A CN106890352A (en) | 2017-03-14 | 2017-03-14 | A kind of bioactive functions dressing for treating diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710149517.0A CN106890352A (en) | 2017-03-14 | 2017-03-14 | A kind of bioactive functions dressing for treating diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106890352A true CN106890352A (en) | 2017-06-27 |
Family
ID=59193707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710149517.0A Pending CN106890352A (en) | 2017-03-14 | 2017-03-14 | A kind of bioactive functions dressing for treating diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106890352A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107397974A (en) * | 2017-09-11 | 2017-11-28 | 北京煜煌科技有限公司 | A kind of wound patch for treating chronic trauma |
| CN107485484A (en) * | 2017-09-01 | 2017-12-19 | 山东汉方生物科技有限公司 | Suitable for general sexual trauma, the wound of chronic trauma patch |
| CN108498843A (en) * | 2018-06-13 | 2018-09-07 | 暨南大学 | A kind of 3 D-printing anti-bacterial hydrogel dressing and preparation method thereof |
| CN109847089A (en) * | 2019-01-30 | 2019-06-07 | 郑岩 | A kind of high molecular material is the wound oxygen supply dressing of carrier multiple film composition |
| CN111317855A (en) * | 2020-02-27 | 2020-06-23 | 温州医科大学 | Three-dimensional composite spongy structure body for promoting diabetic ulcer wound healing and method |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN86102882A (en) * | 1985-04-27 | 1986-10-29 | 昭和电工株式会社 | Dewatering unit |
| CN101165243A (en) * | 2006-10-20 | 2008-04-23 | 东丽纤维研究所（中国）有限公司 | Nano involucra antibiotic textile |
| CN103200971A (en) * | 2010-08-30 | 2013-07-10 | 哈佛大学校长及研究员协会 | A high strength chitin composite material and method of making |
| CN105209084A (en) * | 2013-03-13 | 2015-12-30 | 艾利丹尼森公司 | Improving adhesive properties |
| CN105193545A (en) * | 2014-06-10 | 2015-12-30 | 马修·保罗·普林 | Oppressive bandaging part |
-
2017
- 2017-03-14 CN CN201710149517.0A patent/CN106890352A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN86102882A (en) * | 1985-04-27 | 1986-10-29 | 昭和电工株式会社 | Dewatering unit |
| CN101165243A (en) * | 2006-10-20 | 2008-04-23 | 东丽纤维研究所（中国）有限公司 | Nano involucra antibiotic textile |
| CN103200971A (en) * | 2010-08-30 | 2013-07-10 | 哈佛大学校长及研究员协会 | A high strength chitin composite material and method of making |
| CN105209084A (en) * | 2013-03-13 | 2015-12-30 | 艾利丹尼森公司 | Improving adhesive properties |
| CN105193545A (en) * | 2014-06-10 | 2015-12-30 | 马修·保罗·普林 | Oppressive bandaging part |
Non-Patent Citations (2)
| Title |
|---|
| 何灿忠等: "低蛋白天然胶乳的制备及性能研究", 《橡胶工业》 * |
| 肖玲等: "壳聚糖/壳聚糖季铵盐复合膜的性能研究", 《武汉大学学报（理学版）》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107485484A (en) * | 2017-09-01 | 2017-12-19 | 山东汉方生物科技有限公司 | Suitable for general sexual trauma, the wound of chronic trauma patch |
| CN107397974A (en) * | 2017-09-11 | 2017-11-28 | 北京煜煌科技有限公司 | A kind of wound patch for treating chronic trauma |
| CN108498843A (en) * | 2018-06-13 | 2018-09-07 | 暨南大学 | A kind of 3 D-printing anti-bacterial hydrogel dressing and preparation method thereof |
| CN109847089A (en) * | 2019-01-30 | 2019-06-07 | 郑岩 | A kind of high molecular material is the wound oxygen supply dressing of carrier multiple film composition |
| CN111317855A (en) * | 2020-02-27 | 2020-06-23 | 温州医科大学 | Three-dimensional composite spongy structure body for promoting diabetic ulcer wound healing and method |
| CN111317855B (en) * | 2020-02-27 | 2021-02-26 | 温州医科大学 | Three-dimensional composite spongy structure body for promoting diabetic ulcer wound healing and method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106890352A (en) | A kind of bioactive functions dressing for treating diabetes | |
| Sood et al. | Wound dressings and comparative effectiveness data | |
| Las Heras et al. | Chronic wounds: Current status, available strategies and emerging therapeutic solutions | |
| Kaur et al. | Biomaterials-based regenerative strategies for skin tissue wound healing | |
| Deng et al. | A review of current advancements for wound healing: Biomaterial applications and medical devices | |
| CN206214465U (en) | Skin or surface of a wound combine dressing and its external member | |
| Zhu et al. | Incorporation of ROS-responsive substance P-loaded zeolite imidazolate framework-8 nanoparticles into a Ca2+-cross-linked alginate/pectin hydrogel for wound dressing applications | |
| Zhang et al. | Scarless wound healing programmed by core-shell microneedles | |
| Zhou et al. | Rational design of intelligent and multifunctional dressing to promote acute/chronic wound healing | |
| BRPI0717734B1 (en) | METHOD FOR PREPARING A DRY POWDER FROM POLYMERIC NANOParticles, DRY POWDER AND USE | |
| US20070116750A1 (en) | Compositions for disrupting and inhibiting reconstitution of wound biofilm | |
| Gardikiotis et al. | Borrowing the features of biopolymers for emerging Wound Healing Dressings: a review | |
| Vachhrajani et al. | Science of wound healing and dressing materials | |
| Liu et al. | Research progress on the use of micro/nano carbon materials for antibacterial dressings | |
| Jiang et al. | Nanobiotechnology: applications in chronic wound healing | |
| Mirbagheri et al. | Chitosan-based electrospun nanofibers for diabetic foot ulcer management; recent advances | |
| CN103083712A (en) | Stem cells or other bioactive substances doped surgical dressing | |
| Anniboletti et al. | Clinical activity of innovative non-woven tissues | |
| Liu et al. | Biomembrane-based nanostructure-and microstructure-loaded hydrogels for promoting chronic wound healing | |
| Rivero et al. | Nanofibrous scaffolds for skin tissue engineering and wound healing applications | |
| Cao et al. | Animal tissue-derived biomaterials for promoting wound healing | |
| Çakır et al. | Design of antibacterial bilayered silk fibroin-based scaffolds for healing of severe skin damages | |
| Rashdan et al. | Traditional and modern wound dressings—characteristics of ideal wound dressings | |
| Ren et al. | Effect of composite biodegradable biomaterials on wound healing in diabetes | |
| Tavakoli et al. | Keratin-and VEGF-Incorporated Honey-Based Sponge–Nanofiber Dressing: An Ideal Construct for Wound Healing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170627 |